Feed Insights Top Reports Pricing

⌘K

17:30:16·1022d

SECFilingvia Quantisnow

SEC Form 10-K filed by BioVie Inc.

ByQuantisnow·Wall Street's wire, on your screen.

BIVI· BioVie Inc.

Health Care

Plus alert sent

Quantisnow Plus members were alerted at 17:30:16 ET - 0.9s after publication.

Sign up for Plus

Free Quantisnow account

Get notified the moment BIVI files

Real-time alerts on SEC filings, FDA approvals, analyst ratings, insider trades, and press releases. Follow any ticker. No credit card.

Sign up free Log in

Original source

This insight was delivered by Quantisnow - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIVI (BioVie Inc.) and more on Quantisnow.

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
SEC Form 10-Q filed by BioVie Inc.
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds Follow on Google News

Top lists

Trending By market cap Active companies Insider purchases FDA approvals Short volume screener Sectors Market reports

Browse

By event category By exchange Earnings calendar Dividend tracker Insider tracker IPO calendar Compare stocks

Publish

Publish an article Amend a newsitem Pricing Guidelines Terms

Company

About Pricing Refer a trader25%Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022